AstraZeneca
Zibotentan/Dapagliflozin
Chronic Kidney Disease With High Proteinuria
Countdown
226days
Phase 3 readout · Feb 18, 2027
What's at stake
Phase 3 trial results for Zibotentan/Dapagliflozin in Chronic Kidney Disease With High Proteinuria are due Feb 18, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06087835: Phase 3 trial, sponsor AstraZeneca, drug Zibotentan/Dapagliflozin. Primary completion date 2027-02-18 (estimated).”